Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AANAT | Q16613 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | MMP9 | P14780 | 1/20 | 0.68 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069200 | 0.88 | AANAT (0.77) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL7677886 | 0.88 | MEN1 (0.84) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL6424908 | 0.87 | AANAT (1.00) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL6703004 | 0.87 | AANAT (0.75) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL31114206 | 0.87 | MTNR1A (0.76) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL6424904 | 0.87 | AANAT (0.75) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL761155 | 0.87 | MTNR1A (0.76) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL20227977 | 0.87 | AANAT (0.75) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL12315048 | 0.87 | MEN1 (0.81) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL22446343 | 0.87 | LMNA (0.63) | AANATMEN1KMT2ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212056-B1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | US GOV HEALTH & HUMAN SERV (US) | 2005-12-07 | — | — | EP | claimed |
| EP-1212056-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020002144-A1 | Methods and compositions for bisubstrate inhibitors of acetyltransferases | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2002-01-03 | — | — | US | claimed |
| WO-2001012185-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-02-22 | — | — | WO | claimed |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-25 | — | — | US | disclosed |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | VIVIDION THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2023125751-A1 | DIA-BASED QUANTITATIVE CHEMICAL PROTEOMICS TARGET SCREENING METHOD | 北京大学 | 2023-07-06 | — | — | WO | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-4045050-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | The Scripps Research Institute (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076755-A1 | AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076755-A1 | AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| WO-2017070611-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20060122234-A1 | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors | ARGENTA DISCOVERY LIMITED | 2006-06-08 | — | — | US | disclosed |
| EP-1212056-B1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | US GOV HEALTH & HUMAN SERV (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1525199-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | Argenta Discovery Limited (GB) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004013130-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
| EP-1212056-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020002144-A1 | Methods and compositions for bisubstrate inhibitors of acetyltransferases | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2002-01-03 | — | — | US | disclosed |
| WO-2001012185-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | AANAT 763/4885MEN1 425/4885KMT2A 607/4885 |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | CD4, ICOS, NFATC1 | AANAT 2546/4885MEN1 4604/4885KMT2A 3779/4885 |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | GSTK1, GSTA2, GSTA1 | AANAT 1729/4885MEN1 4768/4885KMT2A 4030/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | AANAT 763/4885MEN1 425/4885KMT2A 607/4885 |
| US-20060122234-A1 | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors | HDAC1, HDAC11, HDAC2 | AANAT 329/4885MEN1 3410/4885KMT2A 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.